The use of theranostic gadolinium-based nanoprobes to improve radiotherapy efficacy

L. Sancey, F Lux, S Kotb, S Roux, S Dufort, A Bianchi, Y Cremillieux, P Fries, J-L Coll, C Rodriguez-Lafrasse, M Janier, M Dutreix, M Barberi-Heyob, F Boschetti, F Denat, C Louis, E Porcel, S Lacombe, G Le Duc, E DeutschJ-L Perfettini, A Detappe, C Verry, R Berbeco, K T Butterworth, S J Mcmahon, K M Prise, P Perriat, O Tillement

Research output: Contribution to journalLiterature review

85 Citations (Scopus)
194 Downloads (Pure)

Abstract

A new efficient type of gadolinium-based theranostic agent (AGuIX®) has recently been developed for MRI-guided radiotherapy (RT). These new particles consist of a polysiloxane network surrounded by a number of gadolinium chelates, usually 10. Owing to their small size (<5 nm), AGuIX typically exhibit biodistributions that are almost ideal for diagnostic and therapeutic purposes. For example, although a significant proportion of these particles accumulate in tumours, the remainder is rapidly eliminated by the renal route. In addition, in the absence of irradiation, the nanoparticles are well tolerated even at very high dose (10 times more than the dose used for mouse treatment). AGuIX particles have been proven to act as efficient radiosensitizers in a large variety of experimental in vitro scenarios, including different radioresistant cell lines, irradiation energies and radiation sources (sensitizing enhancement ratio ranging from 1.1 to 2.5). Pre-clinical studies have also demonstrated the impact of these particles on different heterotopic and orthotopic tumours, with both intratumoural or intravenous injection routes. A significant therapeutical effect has been observed in all contexts. Furthermore, MRI monitoring was proven to efficiently aid in determining a RT protocol and assessing tumour evolution following treatment. The usual theoretical models, based on energy attenuation and macroscopic dose enhancement, cannot account for all the results that have been obtained. Only theoretical models, which take into account the Auger electron cascades that occur between the different atoms constituting the particle and the related high radical concentrations in the vicinity of the particle, provide an explanation for the complex cell damage and death observed.

Original languageEnglish
Article number20140134
Number of pages15
JournalBritish Journal of Radiology
Volume87
Issue number1041
Early online date07 Aug 2014
DOIs
Publication statusPublished - Sep 2014

Keywords

  • NEUTRON-CAPTURE THERAPY
  • GOLD NANOPARTICLES
  • RADIATION-THERAPY
  • IN-VIVO
  • CONTRAST AGENTS
  • MOTEXAFIN GADOLINIUM
  • IONIZING-RADIATION
  • BREAST-CANCER
  • QUANTUM DOTS
  • MRI

Cite this

Sancey, L., Lux, F., Kotb, S., Roux, S., Dufort, S., Bianchi, A., ... Tillement, O. (2014). The use of theranostic gadolinium-based nanoprobes to improve radiotherapy efficacy. British Journal of Radiology, 87(1041), [20140134]. https://doi.org/10.1259/bjr.20140134
Sancey, L. ; Lux, F ; Kotb, S ; Roux, S ; Dufort, S ; Bianchi, A ; Cremillieux, Y ; Fries, P ; Coll, J-L ; Rodriguez-Lafrasse, C ; Janier, M ; Dutreix, M ; Barberi-Heyob, M ; Boschetti, F ; Denat, F ; Louis, C ; Porcel, E ; Lacombe, S ; Le Duc, G ; Deutsch, E ; Perfettini, J-L ; Detappe, A ; Verry, C ; Berbeco, R ; Butterworth, K T ; Mcmahon, S J ; Prise, K M ; Perriat, P ; Tillement, O. / The use of theranostic gadolinium-based nanoprobes to improve radiotherapy efficacy. In: British Journal of Radiology. 2014 ; Vol. 87, No. 1041.
@article{f8582d7fbb85492988cde5647c3d7bb7,
title = "The use of theranostic gadolinium-based nanoprobes to improve radiotherapy efficacy",
abstract = "A new efficient type of gadolinium-based theranostic agent (AGuIX{\circledR}) has recently been developed for MRI-guided radiotherapy (RT). These new particles consist of a polysiloxane network surrounded by a number of gadolinium chelates, usually 10. Owing to their small size (<5 nm), AGuIX typically exhibit biodistributions that are almost ideal for diagnostic and therapeutic purposes. For example, although a significant proportion of these particles accumulate in tumours, the remainder is rapidly eliminated by the renal route. In addition, in the absence of irradiation, the nanoparticles are well tolerated even at very high dose (10 times more than the dose used for mouse treatment). AGuIX particles have been proven to act as efficient radiosensitizers in a large variety of experimental in vitro scenarios, including different radioresistant cell lines, irradiation energies and radiation sources (sensitizing enhancement ratio ranging from 1.1 to 2.5). Pre-clinical studies have also demonstrated the impact of these particles on different heterotopic and orthotopic tumours, with both intratumoural or intravenous injection routes. A significant therapeutical effect has been observed in all contexts. Furthermore, MRI monitoring was proven to efficiently aid in determining a RT protocol and assessing tumour evolution following treatment. The usual theoretical models, based on energy attenuation and macroscopic dose enhancement, cannot account for all the results that have been obtained. Only theoretical models, which take into account the Auger electron cascades that occur between the different atoms constituting the particle and the related high radical concentrations in the vicinity of the particle, provide an explanation for the complex cell damage and death observed.",
keywords = "NEUTRON-CAPTURE THERAPY, GOLD NANOPARTICLES, RADIATION-THERAPY, IN-VIVO, CONTRAST AGENTS, MOTEXAFIN GADOLINIUM, IONIZING-RADIATION, BREAST-CANCER, QUANTUM DOTS, MRI",
author = "L. Sancey and F Lux and S Kotb and S Roux and S Dufort and A Bianchi and Y Cremillieux and P Fries and J-L Coll and C Rodriguez-Lafrasse and M Janier and M Dutreix and M Barberi-Heyob and F Boschetti and F Denat and C Louis and E Porcel and S Lacombe and {Le Duc}, G and E Deutsch and J-L Perfettini and A Detappe and C Verry and R Berbeco and Butterworth, {K T} and Mcmahon, {S J} and Prise, {K M} and P Perriat and O Tillement",
year = "2014",
month = "9",
doi = "10.1259/bjr.20140134",
language = "English",
volume = "87",
journal = "British Journal of Radiology",
issn = "0007-1285",
publisher = "British Institute of Radiology",
number = "1041",

}

Sancey, L, Lux, F, Kotb, S, Roux, S, Dufort, S, Bianchi, A, Cremillieux, Y, Fries, P, Coll, J-L, Rodriguez-Lafrasse, C, Janier, M, Dutreix, M, Barberi-Heyob, M, Boschetti, F, Denat, F, Louis, C, Porcel, E, Lacombe, S, Le Duc, G, Deutsch, E, Perfettini, J-L, Detappe, A, Verry, C, Berbeco, R, Butterworth, KT, Mcmahon, SJ, Prise, KM, Perriat, P & Tillement, O 2014, 'The use of theranostic gadolinium-based nanoprobes to improve radiotherapy efficacy', British Journal of Radiology, vol. 87, no. 1041, 20140134. https://doi.org/10.1259/bjr.20140134

The use of theranostic gadolinium-based nanoprobes to improve radiotherapy efficacy. / Sancey, L.; Lux, F; Kotb, S; Roux, S; Dufort, S; Bianchi, A; Cremillieux, Y; Fries, P; Coll, J-L; Rodriguez-Lafrasse, C; Janier, M; Dutreix, M; Barberi-Heyob, M; Boschetti, F; Denat, F; Louis, C; Porcel, E; Lacombe, S; Le Duc, G; Deutsch, E; Perfettini, J-L; Detappe, A; Verry, C; Berbeco, R; Butterworth, K T; Mcmahon, S J; Prise, K M; Perriat, P; Tillement, O.

In: British Journal of Radiology, Vol. 87, No. 1041, 20140134, 09.2014.

Research output: Contribution to journalLiterature review

TY - JOUR

T1 - The use of theranostic gadolinium-based nanoprobes to improve radiotherapy efficacy

AU - Sancey, L.

AU - Lux, F

AU - Kotb, S

AU - Roux, S

AU - Dufort, S

AU - Bianchi, A

AU - Cremillieux, Y

AU - Fries, P

AU - Coll, J-L

AU - Rodriguez-Lafrasse, C

AU - Janier, M

AU - Dutreix, M

AU - Barberi-Heyob, M

AU - Boschetti, F

AU - Denat, F

AU - Louis, C

AU - Porcel, E

AU - Lacombe, S

AU - Le Duc, G

AU - Deutsch, E

AU - Perfettini, J-L

AU - Detappe, A

AU - Verry, C

AU - Berbeco, R

AU - Butterworth, K T

AU - Mcmahon, S J

AU - Prise, K M

AU - Perriat, P

AU - Tillement, O

PY - 2014/9

Y1 - 2014/9

N2 - A new efficient type of gadolinium-based theranostic agent (AGuIX®) has recently been developed for MRI-guided radiotherapy (RT). These new particles consist of a polysiloxane network surrounded by a number of gadolinium chelates, usually 10. Owing to their small size (<5 nm), AGuIX typically exhibit biodistributions that are almost ideal for diagnostic and therapeutic purposes. For example, although a significant proportion of these particles accumulate in tumours, the remainder is rapidly eliminated by the renal route. In addition, in the absence of irradiation, the nanoparticles are well tolerated even at very high dose (10 times more than the dose used for mouse treatment). AGuIX particles have been proven to act as efficient radiosensitizers in a large variety of experimental in vitro scenarios, including different radioresistant cell lines, irradiation energies and radiation sources (sensitizing enhancement ratio ranging from 1.1 to 2.5). Pre-clinical studies have also demonstrated the impact of these particles on different heterotopic and orthotopic tumours, with both intratumoural or intravenous injection routes. A significant therapeutical effect has been observed in all contexts. Furthermore, MRI monitoring was proven to efficiently aid in determining a RT protocol and assessing tumour evolution following treatment. The usual theoretical models, based on energy attenuation and macroscopic dose enhancement, cannot account for all the results that have been obtained. Only theoretical models, which take into account the Auger electron cascades that occur between the different atoms constituting the particle and the related high radical concentrations in the vicinity of the particle, provide an explanation for the complex cell damage and death observed.

AB - A new efficient type of gadolinium-based theranostic agent (AGuIX®) has recently been developed for MRI-guided radiotherapy (RT). These new particles consist of a polysiloxane network surrounded by a number of gadolinium chelates, usually 10. Owing to their small size (<5 nm), AGuIX typically exhibit biodistributions that are almost ideal for diagnostic and therapeutic purposes. For example, although a significant proportion of these particles accumulate in tumours, the remainder is rapidly eliminated by the renal route. In addition, in the absence of irradiation, the nanoparticles are well tolerated even at very high dose (10 times more than the dose used for mouse treatment). AGuIX particles have been proven to act as efficient radiosensitizers in a large variety of experimental in vitro scenarios, including different radioresistant cell lines, irradiation energies and radiation sources (sensitizing enhancement ratio ranging from 1.1 to 2.5). Pre-clinical studies have also demonstrated the impact of these particles on different heterotopic and orthotopic tumours, with both intratumoural or intravenous injection routes. A significant therapeutical effect has been observed in all contexts. Furthermore, MRI monitoring was proven to efficiently aid in determining a RT protocol and assessing tumour evolution following treatment. The usual theoretical models, based on energy attenuation and macroscopic dose enhancement, cannot account for all the results that have been obtained. Only theoretical models, which take into account the Auger electron cascades that occur between the different atoms constituting the particle and the related high radical concentrations in the vicinity of the particle, provide an explanation for the complex cell damage and death observed.

KW - NEUTRON-CAPTURE THERAPY

KW - GOLD NANOPARTICLES

KW - RADIATION-THERAPY

KW - IN-VIVO

KW - CONTRAST AGENTS

KW - MOTEXAFIN GADOLINIUM

KW - IONIZING-RADIATION

KW - BREAST-CANCER

KW - QUANTUM DOTS

KW - MRI

U2 - 10.1259/bjr.20140134

DO - 10.1259/bjr.20140134

M3 - Literature review

VL - 87

JO - British Journal of Radiology

JF - British Journal of Radiology

SN - 0007-1285

IS - 1041

M1 - 20140134

ER -